Literature DB >> 11002532

[Incidence and prevalence of inflammatory bowel disease in Gijon, Asturias, Spain].

C Saro Gismera1, M Lacort Fernández, G Argüelles Fernández, J Antón Magarzo, R García López, C A Navascues, A Suárez González, G Díaz Alvarez, A González Bernal, A Palacios Galán, A Altadill Arregui, F Vizoso.   

Abstract

AIM: To determine the incidence and prevalence of inflammatory bowel disease in our area and to compare our results with those of other series from Spain and other parts of the world. PATIENTS AND METHODS: Descriptive epidemiologic population study, retrospective (1954-1993) and prospective (1994-1997) in health district V of Gijón in Asturias (Spain) with 225,798 inhabitants. Diagnostic criteria used were those described by Lennard-Jones and Truelove for Crohn's disease and ulcerative colitis and those described by Ashley B. Price for indeterminate colitis. Annual incidence was expressed per 100,000 inhabitants. Prevalence was calculated excluding cured patients: proctocolectomized in ulcerative colitis (10 cases) and deaths (29 cases).
RESULTS: During the period studied, 595 patients were diagnosed with bowel disease (305 patients with ulcerative colitis, 272 with Crohn's disease and 18 with indeterminate colitis). Mean annual incidence (1954-1997) was 6.128 (95% CI: 2.90-9.36). In the 4-year prospective study the incidence was 15.49 (95% CI: 11.19-21.79), 9.36 for ulcerative colitis, 6.08 for Crohn's disease and 0.77 for indeterminate colitis (UC/CD: 1.58). Prevalence was 246.23 (95% CI: 225.6-226.70, 212.79 for ulcerative colitis, 116.47 for Crohn's disease and 7.97 for indeterminate colitis.
CONCLUSIONS: Incidence and prevalence obtained in our environment were higher than those described in other areas of Spain and were similar to those found in areas of Europe and other parts of the world with a higher incidence. Incidence and prevalence have increased since 1980, probably due to the widespread use of endoscopy as a diagnostic technique. Rates were higher in the prospective study than in the retrospective one.

Entities:  

Mesh:

Year:  2000        PMID: 11002532

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  5 in total

Review 1.  Inflammatory bowel diseases: a disease (s) of modern times? Is incidence still increasing?

Authors:  Cristina Saro Gismera; Beatriz Sicilia Aladrén
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

2.  The relation between NOD2/CARD15 mutations and the prevalence and phenotypic heterogeneity of Crohn's disease: lessons from the Israeli Arab Crohn's disease cohort.

Authors:  Amir Karban; Oren Atia; Eran Leitersdorf; Azmi Shahbari; Wisam Sbeit; Zvi Ackerman; Rawia Mualem; Arie Levine; Shula Nesher; Rifaat Safadi; Rami Eliakim
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

Review 3.  Is There a Link Between H. Pylori and the Epidemiology of Crohn's Disease?

Authors:  Ayesha Shah; Nicholas J Talley; Marjorie Walker; Natasha Koloski; Mark Morrison; Daniel Burger; Jane M Andrews; Michael McGuckin; Mike Jones; Gerald Holtmann
Journal:  Dig Dis Sci       Date:  2017-03-09       Impact factor: 3.199

Review 4.  Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials.

Authors:  Yun-Na Song; Ping Zheng; Jun-Hua Xiao; Zhan-Jun Lu
Journal:  Eur J Clin Pharmacol       Date:  2014-06-01       Impact factor: 2.953

5.  EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.

Authors:  María Chaparro; Manuel Barreiro-de Acosta; José Manuel Benítez; José Luis Cabriada; María José Casanova; Daniel Ceballos; María Esteve; Hipólito Fernández; Daniel Ginard; Fernando Gomollón; Rufo Lorente; Pilar Nos; Sabino Riestra; Montserrat Rivero; Pilar Robledo; Cristina Rodríguez; Beatriz Sicilia; Emilio Torrella; Ana Garre; Esther García-Esquinas; Fernando Rodríguez-Artalejo; Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2019-05-21       Impact factor: 4.409

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.